BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of treatments for pulmonary arterial hypertension (PAH) needs to be further investigated. METHODS: Using the COMPERA database, we evaluated the prognostic value of improvements in functional class (FC) and absolute or relative improvements in 6-min walking distance (6MWD) and N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP). In addition, we investigated multicomponent endpoints based on prespecified improvements in FC, 6MWD and NT-proBNP that have been used in recent PAH trials. Finally, we assessed the predictive value of improvements determined by risk stratification tools. The effects of changes from baseline to first follow-up (3-12 months after initiation of PAH therapy) on consecutive survival were determined by Kaplan-Meier analysis with Log-Rank testing and Cox proportional hazard analyses. RESULTS: All analyses were based on 596 patients with newly diagnosed PAH for whom complete data were available at baseline and first follow-up. Improvements in FC were associated with improved survival, whereas absolute or relative improvements in 6MWD had no predictive value. For NT-proBNP, absolute declines conferred no prognostic information while relative declines by ≥35% were associated with better survival. Improvements in multicomponent endpoints were associated with improved survival and the same was found for risk stratification tools. CONCLUSION: While sole improvements in 6MWD and NT-proBNP had minor prognostic relevance, improvements in multicomponent endpoints and risk stratification tools based on FC, 6MWD, and NT-proBNP were associated with improved survival. These tools should be further explored as outcome measures in PAH trials.

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials. a COMPERA analysis / Hoeper, M. M.; Pausch, C.; Olsson, K. M.; Huscher, D.; Pittrow, D.; Grunig, E.; Staehler, G.; Vizza, C. D.; Gall, H.; Distler, O.; Opitz, C.; Gibbs, J. S. R.; Delcroix, M.; Ghofrani, H. A.; Ewert, R.; Kaemmerer, H.; Kabitz, H. -J.; Skowasch, D.; Behr, J.; Milger, K.; Halank, M.; Wilkens, H.; Seyfarth, H. -J.; Held, M.; Dumitrescu, D.; Tsangaris, I.; Vonk-Noordegraaf, A.; Ulrich, S.; Klose, H.; Claussen, M.; Eisenmann, S.; Schmidt, K. -H.; Rosenkranz, S.; Lange, T. J.. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - 41:7(2022), pp. 971-981. [10.1016/j.healun.2022.03.011]

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials. a COMPERA analysis

Vizza C. D.;Klose H.;
2022

Abstract

BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of treatments for pulmonary arterial hypertension (PAH) needs to be further investigated. METHODS: Using the COMPERA database, we evaluated the prognostic value of improvements in functional class (FC) and absolute or relative improvements in 6-min walking distance (6MWD) and N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP). In addition, we investigated multicomponent endpoints based on prespecified improvements in FC, 6MWD and NT-proBNP that have been used in recent PAH trials. Finally, we assessed the predictive value of improvements determined by risk stratification tools. The effects of changes from baseline to first follow-up (3-12 months after initiation of PAH therapy) on consecutive survival were determined by Kaplan-Meier analysis with Log-Rank testing and Cox proportional hazard analyses. RESULTS: All analyses were based on 596 patients with newly diagnosed PAH for whom complete data were available at baseline and first follow-up. Improvements in FC were associated with improved survival, whereas absolute or relative improvements in 6MWD had no predictive value. For NT-proBNP, absolute declines conferred no prognostic information while relative declines by ≥35% were associated with better survival. Improvements in multicomponent endpoints were associated with improved survival and the same was found for risk stratification tools. CONCLUSION: While sole improvements in 6MWD and NT-proBNP had minor prognostic relevance, improvements in multicomponent endpoints and risk stratification tools based on FC, 6MWD, and NT-proBNP were associated with improved survival. These tools should be further explored as outcome measures in PAH trials.
2022
clinical trials; endpoints; mortality; pulmonary arterial hypertension; risk; treatment
01 Pubblicazione su rivista::01a Articolo in rivista
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials. a COMPERA analysis / Hoeper, M. M.; Pausch, C.; Olsson, K. M.; Huscher, D.; Pittrow, D.; Grunig, E.; Staehler, G.; Vizza, C. D.; Gall, H.; Distler, O.; Opitz, C.; Gibbs, J. S. R.; Delcroix, M.; Ghofrani, H. A.; Ewert, R.; Kaemmerer, H.; Kabitz, H. -J.; Skowasch, D.; Behr, J.; Milger, K.; Halank, M.; Wilkens, H.; Seyfarth, H. -J.; Held, M.; Dumitrescu, D.; Tsangaris, I.; Vonk-Noordegraaf, A.; Ulrich, S.; Klose, H.; Claussen, M.; Eisenmann, S.; Schmidt, K. -H.; Rosenkranz, S.; Lange, T. J.. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - 41:7(2022), pp. 971-981. [10.1016/j.healun.2022.03.011]
File allegati a questo prodotto
File Dimensione Formato  
Hoeper,_Prognostic_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1634117
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact